Bordetella pertussis MPLA and riboflavin as adjuvants for trivalent influenza vaccine

Adjuvanted trivalent influenza vaccines containing 3.75 ？μg of each antigen strain with alum and riboflavin or Bordetella pertussis MPLA were tested in mice. Immune response was evaluated by haemagglutination inhibition test, ELISA and antibody affinity test. The highest increase in antibody titers was obtained with the formulation containing MPLA. Significant increase in HAI titer was observed when mice received the formulation containing MPLA and alum, with a clear cross reaction between B lineages. Corroborating our previous results with monovalent vaccine, this study confirmed the adjuvant formulations containing MPLA or Riboflavin as promising adjuvants to be evaluated in clinical trials